<!DOCTYPE html>
<html>
<head>
	<title>Genomics England - Rare Diseases - Familial breast cancer</title>
	<meta charset="utf-8" />
	<script type="text/javascript" src="inc/jquery.min.js"></script>
	<link rel="stylesheet" type="text/css" href="inc/style.css" />
	<!-- <script src="../file/js/modernizr.js"></script>  -->
</head>
<body>
	<div class="container">
		<h1>Familial breast cancer</h1>
		<div id="nav">
			<br /><br /><a href="index.html" style="margin-left:20px;">&#171; Back to homepage</a>
		</div>			
		<div class="main">
			<ul class="tabs">
				<li>
					<input type="radio" checked name="tabs" id="tab1">
					<label for="tab1">Eligibility</label>
					<div id="tab-content1" class="tab-content animated fadeIn">
						<!-- <h2>Familial breast cancer eligibility</h2> -->


<h3>Inclusion Criteria</h3>
Multiplex cases:<br />
Proband is affected by invasive breast cancer (age <50)<br />
- 3 family members (FDR, SDR, TDR) affected by invasive breast cancer (average age of BCs <60) or ovarian cancer (any age). <br />
- Samples available and to be collected from >= 2 affected relatives<br />
Proband only recruitment:<br />
- Proband is affected by breast cancer (age <50) or ovarian cancer (any age). <br />
- Manchester Score of family >22 <br />
- Cases of ovarian cancer (any age) and breast cancer (<40) have been confirmed. <br />
- Ovarian cancers demonstrated to be invasive epithelial; mucinous and borderline tumours non-eligible (where histology available) <br />
- Family is not eligible for recruitment to the multiplex families breast cancer eligibility. <br />
- Samples to be supplied from: proband only.<br />
<br />
Unaffected individuals should not be recruited in this disorder.

<h3>Exclusion Criteria</h3>


<h3>Prior Genetic Testing</h3>
Testing as below is strongly recommended PRIOR TO RECRUITMENT to allow appropriate management of families with readily detectable mutations in known disease genes:<br />
- BRCA1 <br />
- BRCA2

<h3>Genes</h3>
Testing as below is strongly recommended PRIOR TO RECRUITMENT to allow appropriate management of families with readily detectable mutations in known disease genes:<br />
- BRCA1 <br />
- BRCA2

<h3>Closing Statement</h3>
These requirements will be kept under continual review during the main programme and may be subject to change.

					</div>
				</li>
				<li>
					<input type="radio" name="tabs" id="tab2">
					<label for="tab2">Phenotypes</label>
					<div id="tab-content2" class="tab-content animated fadeIn">
						<!-- <h2>Familial breast cancer phenotypes</h2> -->

	<h3><a href="http://purl.obolibrary.org/obo/HP_0003002" onclick="window.open(this.href);return false;">Breast carcinoma</a></h3>
	The presence of a carcinoma of the breast.
	<h3><a href="http://purl.obolibrary.org/obo/HP_0100615" onclick="window.open(this.href);return false;">Ovarian neoplasm</a></h3>
	A tumor (abnormal growth of tissue) of the ovary.

					</div>
				</li>
				<li>
					<input type="radio" name="tabs" id="tab3">
					<label for="tab3">Clinical Tests</label>
					<div id="tab-content3" class="tab-content animated fadeIn">
						Clinical tests are not available
					</div>
				</li>				
			</ul>
		</div>		
	</div>		
</body>
</html>